The cost of vaccinating a child in the world's poorest countries is much higher than it was in 2001--68 times higher, according to Medecins Sans Frontieres. The international charity has a problem with that, and it's asking pneumococcal disease vaccine makers Pfizer and GlaxoSmithKline to fix it.
SINGAPORE-- If Unichem Laboratories' third-quarter earnings report of net profits of only $334,316 (converted from Indian rupees) is any indication, Lupin and Mylan's India unit can soon be expected to reveal huge reductions for the period. They, Slovenian Krka and Teva Pharmaceutical were fined a total of $427.7 million last summer by the European Commission for allegedly accepting pay for delay from France's Servier.
India's state of Himachal Pradesh, known as Asia's pharmaceutical hub, is taking steps to make its bulk-drug industry more attractive to foreign and other investors, but finds attempting to do so a hard slog. The action, and that of other states, is considered key to reducing India's reliance on imports of active pharmaceutical ingredients, mainly from China.
Gilead Sciences said that an India patent office ruling on hepatitis C drug Sovaldi (sofosbuvir) only affects an application covering part of the active ingredient and that the larger validity of the uniqueness of the product remains intact as does a path-breaking patient access for the drug.
India's intellectual-property police nixed a key patent on Gilead Sciences' hepatitis C drug Sovaldi, opening the door for cheap generic copies from domestic drugmakers such as Natco Pharma. It's the latest blow to a multinational drugmaker's ambitions in India, which remains one of the fastest-growing drug markets in the world.
China's FDA has awarded marketing approval of the world's first Sabin strain inactivated polio vaccine, marking a milestone as well for the Institute of Medical Biology of the Academy of Medical Sciences.
GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.
In the coming year, you can expect to see a lot more work being done on Asian deals, particularly for China. Through the course of this past year there have been growing signs of this global evolution.
Companies in Egypt have been advertising Indian-made versions of Gilead Sciences' hepatitis C cure Sovaldi for sale. The problem is, none of the 7 drugmakers that were granted the right to produce the drug, 6 of them Indian companies, have gotten past development with the product. That suggests that whatever is being sold in Egypt is not really generic Sovaldi.
As med tech companies set their sails toward China, a new trade agreement between the U.S. and Chinese governments looks to ease restrictions for imports, paving the way for greater expansion by U.S. devicemakers.